Applied Health Economics and Health Policy

, Volume 12, Issue 3, pp 267–277

A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

Systematic Review

DOI: 10.1007/s40258-013-0078-1

Cite this article as:
Mikyas, Y., Agodoa, I. & Yurgin, N. Appl Health Econ Health Policy (2014) 12: 267. doi:10.1007/s40258-013-0078-1

Abstract

Background and objective

Male osteoporosis is an increasingly important public health concern. Although several medications are approved for the treatment of osteoporosis, medication non-adherence and the associated consequences are not well documented in male populations. Our objective was to identify and summarize the current knowledge related to osteoporotic medication adherence, the potential implications of non-adherence to the medication, and the cost of osteoporosis-related fractures and health-resource utilization in men.

Methods

Two separate systematic searches were conducted concurrently: one to identify literature reporting male-specific adherence to anti-osteoporotic medication and the clinical consequence of non-adherence in men, and the other to identify literature reporting the cost and resource burden of osteoporosis-related fractures in men. The PubMed, MEDLINE, EMBASE, and Cochrane databases were searched using a date range of 1 January 1998 to 30 June 2012, and citations were screened based on pre-defined criteria.

Results

The percentage of males adherent to bisphosphonates [medication possession ratio (MPR) >0.8] over a 1-year period ranged from 32 % to 64 %. The data imply worse clinical outcomes with treatment non-adherence. Costs and resource use associated with osteoporosis-related fractures in men are high, with hip fractures generating the most cost.

Conclusions

One-third to two-thirds of men are not adherent to bisphosphonates. Non-adherence is associated with increased fracture risk. Estimates of direct and indirect osteoporosis-related fracture costs are also substantial in men, and may even be more costly than in women. More robust data would better inform disease management initiatives that could improve adherence to medication and outcomes in men with osteoporosis.

Supplementary material

40258_2013_78_MOESM1_ESM.docx (184 kb)
Supplementary material 1 (DOCX 184 kb)

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Amgen IncOne Amgen Center DriveThousand OaksUS